Heidelberg, Germany -- Novaliq GmbH a drug delivery company with focus on technologies for poorly soluble
drugs for ophthalmic and topical applications has today announced the successfully
completion of a financing round of € 2.3 Mio. Since its foundation in the year 2004
the company has raised € 9,3 Million in three finance rounds.
Investor is again the investment company of SAP co-founder Dietmar Hopp, dievini
Hopp Bio Tech holding GmbH & Co. KG. With the new funds the company intends to
advance its lead projects into clinical development and to strengthen and broaden
the technology platform.
“We are pleased about the ongoing confidence and support from our investor in order
to systematically develop the company with our technology platform”, Bernhard
Günther, Managing Director and co-founder of Novaliq says.
“Since its foundation Novaliq has developed in line with the business plan and even
better. We see a big potential and numerous applications for the technology platform
which we continue to support with this new financing” says Friedrich von Bohlen.
Managing Director of dievini.
NOVALIQ GmbH is a drug delivery company whose goal is to develop innovative
pharmaceutical formulations. The patented semifluorinated alkanes (SFAs) can be
used in various routes of administration for the transport of drugs or oxygen for
therapeutic purposes. Based on its unique physicochemical properties, Novaliq
currently develops innovative ophthalmic and dermatological formulations as well as
solutions for organ preservation and has several product candidates with excellent
market potential in various stages of preclinical and clinical development.